|
Jan 3
|
Telix to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 18
|
Telix Submits Biologics License Application (BLA) for TLX250-CDx (Zircaix™) for Imaging of Kidney Cancer
|
|
Dec 6
|
Positive Topline Results from Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer Presented at SABCS
|
|
Dec 4
|
First Patient Dosed in European Named Patient (Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent
|
|
Nov 29
|
Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS
|
|
Nov 8
|
Telix to Present at Jefferies London Healthcare Conference 2023
|
|
Nov 8
|
Telix and Wiik Pharma Sign Distribution Agreement for Illuccix® in the Nordic Region
|
|
Sep 27
|
HRH Princess Astrid of Belgium visits Telix's New European Manufacturing Facility in Brussels South
|
|
Jul 19
|
Telix Reports Continued Double-Digit Revenue Growth and Positive Operating Cash Flow
|
|
Jul 18
|
First Patient Dosed in STARSTRUCK Study of TLX250 Targeted Radiation Therapy in Combination with Merck Investigational DNA-PK Inhibitor, Peposertib
|